Special Issue "Hematopoietic Cell Transplantation and Cellular Therapy: A New Era"
Deadline for manuscript submissions: 31 May 2019
Dr. Celalettin Ustun
Division of Hematology, Oncology and Transplantation, Rush University, 600 S. Paulina St., Chicago, Il 60612, USA
Website | E-Mail
Interests: hematopoietic cell transplantation; allogeneic; graft-versus-host disease; organ-health evaluations before transplantation; alternative donors; cellular therapy
In this Special Issue, we will try to capture all the new and exciting developments in “old” hematopoietic cell transplantation (HCT) and “new” cellular therapy. In HCT, there are significant changes, especially in alternative donors (e.g., haploidentical transplantation and umbilical cord blood (UCB) transplantation). The use of haploidentical transplantation has been increasing while UCB transplantation is declining. However, it does not mean UCB HCT has no place in the HCT world any longer. The differences between UCB HCT immune recovery and other resources could be beneficial. Translational research is still on-going in UCB HCT. What needs to be done to improve haploidentical HCT? There are new, FDA approved drugs for graft-versus-host disease (GVHD) after decades with no development, new agents are actively investigated in GVHD prophylaxis studies. Two industrial CAR T cells have been approved for lymphoid malignancies already. Many studies are underway for patients with hematologic malignancies. What is happening in supportive care, infectious disease relevant to HCT?In this very exciting era of HCT and cellular therapy, experts will share literature reviews, their own experiences, and comments in this Special Issue.
Dr. Celalettin Ustun
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Hematopoietic cell transplantation
- Cellular therapy
- Haploidentical transplantation
- Umbilical cord blood
- Translational research
- Graft-versus-host diseases
- Hematologic malignancies
- Lymphoid malignancies
- CAR T cells